Celcuity, Inc. (NASDAQ:CELC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Celcuity, Inc. (NASDAQ:CELC) have received an average recommendation of “Moderate Buy” from the eleven research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $154.5455.

Several equities research analysts have recently weighed in on CELC shares. Leerink Partners set a $155.00 price target on Celcuity in a report on Tuesday, June 2nd. Stifel Nicolaus dropped their price objective on Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a report on Friday, August 14th. Citigroup reaffirmed a “market outperform” rating on shares of Celcuity in a research report on Monday, August 17th. Citizens Jmp reiterated a “market outperform” rating and issued a $177.00 target price on shares of Celcuity in a research note on Monday, August 17th. Finally, Needham & Company LLC decreased their target price on Celcuity from $157.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, August 14th.

Celcuity Stock Performance

Shares of NASDAQ:CELC opened at $83.45 on Monday. The company has a market capitalization of $4.08 billion, a price-to-earnings ratio of -19.41 and a beta of 0.19. Celcuity has a 12 month low of $44.42 and a 12 month high of $151.02. The firm’s 50-day moving average is $92.98 and its 200 day moving average is $106.20. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28). Research analysts predict that Celcuity will post -4.75 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CELC. EverSource Wealth Advisors LLC boosted its position in Celcuity by 1,329.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after buying an additional 319 shares during the period. US Bancorp DE grew its stake in Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after acquiring an additional 1,167 shares during the period. Parallel Advisors LLC purchased a new position in shares of Celcuity during the first quarter worth approximately $38,000. Finally, Meeder Asset Management Inc. bought a new stake in shares of Celcuity during the fourth quarter valued at approximately $42,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a biotechnology company focused on advancing personalized medicine through functional diagnostics. Its technology is designed to analyze living tumor cells obtained from patient tissue and identify abnormal signaling activity that may influence how a cancer responds to specific therapies.

The company’s primary platform, CELsignia, uses proprietary assays to measure the activity of cellular signaling pathways in a patient’s tumor cells. Celcuity develops these tests for use in oncology drug development, patient selection, and potentially as companion diagnostics to help identify patients who are most likely to benefit from targeted treatments.

Celcuity works with biopharmaceutical companies and research organizations to evaluate drug-response biomarkers and support precision oncology programs.